

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

INSIDE INFORMATION ANNOUNCEMENT

PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the Announcement [2019] No. 22 “Guidelines for the “Full Circulation” Application for Domestic Unlisted Shares of H-share Listed Companies” (《H 股公司境內未上市股份申請「全流通」業務指引》) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019.

In view of the aforementioned announcement, the board of directors of the Company (the “**Board**”) is pleased to announce that, on August 20, 2021, the Company submitted an application in relation to H share full circulation to the CSRC in order to convert 192,592,582 domestic shares and unlisted foreign shares of the Company (the “**Domestic Shares and Unlisted Foreign Shares**”) into H shares (the “**H Shares**”). Upon obtaining all necessary approvals (including approvals from the CSRC and the Stock Exchange) and having complied with all applicable laws, rules and regulations, the Domestic Shares and Unlisted Foreign Shares shall be converted into H Shares and the Company will apply for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”). According to the articles of association of the Company, the Conversion and Listing does not require holding of any shareholders’ meeting or class meeting for approval.

As of the date of this announcement, the details of implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the requirements under the Inside Information Provisions and the Listing Rules.

The Conversion and Listing is still subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other domestic and foreign regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, August 20, 2021

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. YU Kwok Kuen Harry as independent non-executive directors.